Data For Teva's Azilect Not Good Enough For Claim Of Slowing Parkinson's Progression, FDA Panel Says
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA advisory committee reluctant to set precedent for disease modification indication without strong data.